OCTAVE induction 1 (n=475) | Sample of UC cohort (n=28) | |
Male sex, n (%) | 277 (58.2) | 16 (57) |
Age, years | 41.3±14.1 | 43.2±14.4 |
Duration of disease, years | ||
Median | 6.5 | 10.2 |
Range | 0.3–42.5 | 2.2–51.4 |
Extent of disease, n/total n (%) | ||
Proctosigmoiditis | 64/475 (13.7) | 3/28 (10.7) |
Left-sided colitis | 158/475 (33.3) | 6/28 (21.4) |
Extensive colitis/pancolitis | 252/475 (53.1) | 19/28 (67.9) |
Total Mayo score | 9.0±1.4 | 8.5±1.8 |
Partial Mayo score | 6.3±1.2 | 6±1.6 |
CRP, mg/L | ||
Median | 4.4 | 5.8 |
Range | 0.1–208.4 | 0.8–70.6 |
Glucocorticoid use at baseline* | 214 (45.0) | 17 (60.7) |
Previous treatment with TNF inhibitor, n (%) | 254 (53.4) | 28 (100) |
Previous treatment failure, n (%) | ||
TNF inhibitor | 243 (51.1) | 28 (100) |
Glucocorticoid | 350 (73.5) | 24 (85.7) |
Immunosuppressant | 360 (75.6) | 21 (75) |
Panés et al9 (n=86) | Sample of CD cohort (n=13) | |
Female, n (%) | 47 (54.7) | 9 (69.2) |
Age, years | ||
Mean (SD) | 39.3 (13.7) | 39.7 (19.5) |
Weight, kg | ||
Mean (SD) | 71.6 (18.8) | 69.9 (16.3) |
Race, n (%) | ||
White | 72 (83.7) | 9 (69.2) |
Black | 2 (2.3) | 0 (0) |
Asian | 11 (12.8) | 1 (7.7) |
Others | 1 (1.2) | 0 (0) |
Duration since CD diagnosis, years | ||
Mean (SD) | 11.3 (9.7) | 14.4 (8.2) |
Extent of disease, n (%) | ||
L1 (Ileal) | 7 (8.1) | 1 (7.7) |
L1/4 (Ileal + Upper GI) | 2 (2.3) | 2 (15.4) |
L2 (Colonic) | 5 (5.8) | 0 (0) |
L2/4 (Colonic + Upper GI) | 16 (18.6) | 1 (7.7) |
L3 (Ileocolonic) | 15 (17.4) | 4 (30.8) |
L3/4 (Ileocolonic) | 39 (45.3) | 5 (38.5) |
Prior use of TNF inhibitor, n (%) | 66 (76.7) | 13 (100) |
Use of corticosteroids at study entry, n (%) | 28 (32.6) | 7 (53.8) |
Baseline CDAI score | ||
Mean (SD) | 320 (61.66) | 374 (183.73) |
Baseline CRP, mg/L | ||
Median (min-max) | 5.5 (0.2–126) | 28.7 (3.5–107) |
Within each pair of columns, the left columns corresponds to the patient demographics of the tofacitinib-assigned arm in corresponding RCTs (eg, the OCTAVE trials reported by Sandborn et al, the CD trials reported by Panés et al). The right columns reports the corresponding demographics of a sample of tofacitinib-treated patients at UCSF. Treatment failure is defined as an inadequate response to any treatment (eg, steroids, TNF inhibitor) as defined and documented by the treating clinician.
CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; RCTs, randomised controlled trials; TNF, tumour necrosis factor; UCSF, University of California, San Francisco.